iMAGiNE™ Platform for Clinical Decision Support
Major Depressive Disorder, ADHD, PTSD, OCD, Schizophrenia
DevelopmentActive
Key Facts
Indication
Major Depressive Disorder, ADHD, PTSD, OCD, Schizophrenia
Phase
Development
Status
Active
Company
About Sama Therapeutics
Sama Therapeutics is an AI-driven neuropsychiatry company developing a predictive biomarker platform, iMAGiNE™, to reshape brain health diagnostics and therapeutic development. The company integrates generative AI with computational neuroscience to create digital tools that de-risk clinical trials, assist providers in treatment selection, and empower individuals to track brain function. Founded in 2018, Sama operates as a private, likely pre-revenue platform company targeting a significant unmet need in mental health and neurology through a data-driven, transdiagnostic approach.
View full company profile